drugset / Trial / NCT02716857

Efficacy and Safety of Egalet-002 in Patients With Moderate-to-Severe Chronic Low Back Pain

NCT02716857

Phase 3 Completed 549 enrolled Egalet Ltd
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine the analgesic efficacy of Egalet-002 twice daily (BID) in patients with moderate-to-severe chronic low back pain

Timeline

Start
2016-03
Primary completion
2017-08
Completion
2017-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxycodone Other / unclassified

Indications

No indication recorded.